Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William S Dalton

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Cancer Treatment Reviews|May 10, 2003
The tumor microenvironment: focus on myelomaWilliam S Dalton
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
The "total cancer care" concept: linking technology and health careWilliam S Dalton
Seminars in Oncology|January 10, 2003
Drug resistance and drug development in multiple myelomaWilliam S Dalton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002William S Dalton
Oncology (Williston Park, N.Y.)|February 4, 2005
Proteasome inhibition in hematologic malignancies: clinical update and practical applicationsWilliam S Dalton
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
The tumor microenvironment as a determinant of drug response and resistanceWilliam S. Dalton
Seminars in Oncology|April 1, 2005
The proteasomeWilliam S Dalton
Molecular Cancer Therapeutics|January 9, 2003
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discoveryKenneth C Anderson, William S Dalton
Science (New York, N.Y.)|May 27, 2006
Cancer biomarkers--an invitation to the tableWilliam S Dalton, Stephen H Friend
Expert Review of Hematology|November 19, 2010
Environmental-mediated drug resistance: a target for multiple myeloma therapyKenneth H Shain, William S Dalton
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Cancer Treatment Reviews|May 10, 2003
The tumor microenvironment: focus on myelomaWilliam S Dalton
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
The "total cancer care" concept: linking technology and health careWilliam S Dalton
Seminars in Oncology|January 10, 2003
Drug resistance and drug development in multiple myelomaWilliam S Dalton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002William S Dalton
Oncology (Williston Park, N.Y.)|February 4, 2005
Proteasome inhibition in hematologic malignancies: clinical update and practical applicationsWilliam S Dalton
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
The tumor microenvironment as a determinant of drug response and resistanceWilliam S. Dalton
Seminars in Oncology|April 1, 2005
The proteasomeWilliam S Dalton
Molecular Cancer Therapeutics|January 9, 2003
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discoveryKenneth C Anderson, William S Dalton
Science (New York, N.Y.)|May 27, 2006
Cancer biomarkers--an invitation to the tableWilliam S Dalton, Stephen H Friend
Expert Review of Hematology|November 19, 2010
Environmental-mediated drug resistance: a target for multiple myeloma therapyKenneth H Shain, William S Dalton
Pageof 9